loading page

DC-T cell axis is an effective target for treating non-small cell lung cancer
  • +7
  • Shuangcui Wang,
  • Guan Zhang,
  • qian cui,
  • Yanjie Yang,
  • Dong Wang,
  • Aqing Liu,
  • Ying Xia,
  • Wentao Li,
  • Yunhe Liu,
  • Jianchun Yu
Shuangcui Wang
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Guan Zhang
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
qian cui
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Yanjie Yang
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Dong Wang
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Aqing Liu
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Ying Xia
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Wentao Li
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Yunhe Liu
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Author Profile
Jianchun Yu
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Corresponding Author:[email protected]

Author Profile

Abstract

The DC-T cell axis is a bridge connecting innate immunity and adaptive immunity. The initial immune response against tumors is mainly induced by mature antigen-presenting dendritic cells (DC). Enhancing the crosstalk between DC and T cells could improve the immune response to non-small cell lung cancer. This article reviews the interaction between DC-T cells in the treatment of non-small cell lung cancer and how this interaction impacts the treatment outcome.
13 Apr 2023Submitted to Immunity, Inflammation and Disease
19 Apr 2023Submission Checks Completed
19 Apr 2023Assigned to Editor
19 Apr 2023Review(s) Completed, Editorial Evaluation Pending
25 Apr 2023Reviewer(s) Assigned
18 Oct 2023Editorial Decision: Revise Minor
30 Oct 20231st Revision Received
02 Nov 2023Submission Checks Completed
02 Nov 2023Assigned to Editor
02 Nov 2023Review(s) Completed, Editorial Evaluation Pending
02 Nov 2023Reviewer(s) Assigned
02 Nov 2023Editorial Decision: Revise Minor
06 Nov 20232nd Revision Received
06 Nov 2023Assigned to Editor
06 Nov 2023Submission Checks Completed
06 Nov 2023Review(s) Completed, Editorial Evaluation Pending
09 Nov 2023Reviewer(s) Assigned
09 Nov 2023Editorial Decision: Accept